Translational research bridges the gap from basic science in the lab to clinical practice, in order to enhance human health and well-being. It’s sometimes referred to as bench to bedside to community. Research is most effective when clinicians and scientists work together and a key role of NZSO is to encourage collaboration between clinicians and scientists. Creating an opportunity for our community to collaborate to bring the greatest benefit to New Zealanders impacted by cancer.
Could you be the next recipient? Get inspired!
Check out
Dr Jim Smith and his multidisciplinary team of New Zealand experts in epigenomics have won the 2024 Roche Translational Cancer Research Fellowship (RTCRF).
The aim of their research project is to develop a targeted ctDNA-based DNA methylation panel for implementation alongside PSA, MRI, and other risk stratification data in a structured screening approach for men at risk of prostate cancer.
Dr Smith believes this innovative research programme will contribute to early prostate cancer detection, leading to improved survival, fewer unnecessary procedures, decreased cost of care, and a more equitable screening approach for NZ men.
Read more about Dr Jim Smith’s and Associate Professor Aniruddha Chatterjee’s work
© 2025, Roche Products (New Zealand) Ltd, Auckland. This site is intended for New Zealand audiences. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site.
M-NZ-00000625-v20.0/MR10379/DEC24. This site was last updated December2024.